AI Insight
Researchers developed and validated an improved analytical method for detecting free polyethylene glycol (PEG) contamination in PEGylated peptide drugs using reverse-phase high-performance liquid chromatography combined with charged aerosol detection (RP-HPLC-CAD). By co-optimizing specific detector parameters (power function value and power law settings), they achieved a linear detector response across a broad concentration range, overcoming limitations of conventional detection methods. The method demonstrated good specificity, precision, linearity, accuracy, and robustness when tested on three different PEGylated peptide therapeutics and multiple drug batches.
Why it matters
This method provides pharmaceutical manufacturers with a more sensitive and reliable quality control tool for detecting free PEG impurities in PEGylated peptide drugs, which is critical for ensuring drug safety and efficacy. The technique's compatibility with gradient elution and improved sensitivity over existing methods could enhance routine quality control processes in pharmaceutical production.
Understand the Science
by Yue Sun, Xinyue Hu, Yue Huang, Yuqin Yang, Xiaoming Zhang, Yi Li, Ping Lyu, Jing Li
PEGylation is a well-established strategy used to enhance the pharmacokinetic and pharmacodynamic properties of peptide drugs. However, free polyethylene glycol (PEG) remains a critical process-related impurity. Conventional detection methods for nonchromophoric compounds such as PEG, which include the use of evaporative light scattering (ELS) and refractive index (RI) detectors, are limited by their low sensitivity and poor compatibility with the gradient elution. Herein, systematically optimized reverse-phase high-performance liquid chromatography (RP-HPLC) coupled with charged aerosol detection (CAD) was developed and validated for the quantification of free PEG in three representative PEGylated peptide therapeutics: PEG-loxenatide, pegmolesatide, and visepegenatide. The proposed method implements a co-optimization strategy for CAD parameters, with the power function value (PFV) applied during CAD signal acquisition and the power law(PL) setting adjusted during data processing.This dual optimization effectively linearizes the inherently nonlinear CAD response across a broad concentration range, enabling a linear relationship between PEG concentration and detector response. Method validation demonstrated satisfactory specificity, precision, linearity, accuracy, robustness, and solution stability in accordance with the applicable guidelines and pharmacopoeial requirements. Practical applicability was confirmed by analyzing multiple drug batches and accelerated stability samples.A Wilcoxon signed-rank test showed no statistically significant difference between the results obtained under the default and co-optimized settings (P > 0.05), indicating that the two settings produced comparable results under the conditions evaluated. The proposed HPLC-CAD method provides a practical analytical approach in the analysis of PEGylated peptide pharmaceuticals by achieving a linearized CAD response through PFV and PL co-optimization, providing an effective approach for free PEG quantification in routine quality control.